Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CurveBeam AIASX:CVB EV-to-EBIT is -1.42 as of Jul. 22, 2026. The stock has 5 warning signs investors should review. Among 465 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 215053.55% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CurveBeam AI's Enterprise Value for the quarter that ended in Dec. 2025 was A$48.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CurveBeam AI's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CurveBeam AI EV-to-EBIT Related Terms
CurveBeam AI EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CurveBeam AI's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CurveBeam AI's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CurveBeam AI EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CurveBeam AI's EV-to-EBIT falls into.
CurveBeam AI's current Enterprise Value is A$21.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CurveBeam AI's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CurveBeam AI (ASX:CVB) has a EV-to-EBIT of -1.42 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CurveBeam AI and its competitors. According to the industry distribution chart, CurveBeam AI ranks #999999 out of 465 companies in the Medical Devices & Instruments industry.
Is CurveBeam AI's EV-to-EBIT too high?
CurveBeam AI's current EV-to-EBIT is -1.42. Based on the distribution chart, CurveBeam AI ranks #999999 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CurveBeam AI's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #999999 out of 465 companies for EV-to-EBIT. This places CurveBeam AI in the lower half of its industry. The industry median EV-to-EBIT is 18.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.28, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current EV-to-EBIT is -1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current EV-to-EBIT of -1.42. The current EV-to-EBIT is -1.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current EV-to-EBIT is -1.42 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 
